Status:
COMPLETED
Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
Lead Sponsor:
Handok Inc.
Conditions:
Healthy Volunteers
Eligibility:
All Genders
19+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to compare the pharmacokinetics and safety of HD-P023 and coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers
Eligibility Criteria
Inclusion
- Patients who are 19 years or older on screening
- Signed informed consent
- Healthy Volunteer
- Other inclusion applies
Exclusion
- Clinically relevant/significant findings as evaluated by the investigator
- Other exclusion applied
Key Trial Info
Start Date :
March 26 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 7 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06889350
Start Date
March 26 2025
End Date
May 7 2025
Last Update
July 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
H Plus Yangji Hospital
Seoul, Seoul, South Korea, 08779